- Intellipharmaceutics International (IPCIQ) Company Profile Description
Intellipharmaceutics International Inc , a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States
- Intellipharmaceutics International Inc. (IPCIQ) - Yahoo Finance
Find the latest Intellipharmaceutics International Inc (IPCIQ) stock quote, history, news and other vital information to help you with your stock trading and investing
- IPCIQ Stock Price Quote | Morningstar
See the latest IntelliPharmaCeutics International Inc stock price (IPCIQ:PINX), related news, valuation, dividends and more to help you make your investing decisions
- IPCIQ Intellipharmaceutics International Inc. - Seeking Alpha
A high-level overview of Intellipharmaceutics International Inc (IPCIQ) stock View (IPCIQ) real-time stock price, chart, news, analysis, analyst reviews and more
- Intellipharmaceutics International - LinkedIn
At Intellipharmaceutics, we are engaged in the research, development and commercialization of pharmaceutical products, both novel and generic, with a particular emphasis in the controlled-release
- Intellipharmaceutics International Inc. et al - KPMG Canada
Intellipharmaceutics International Inc (" IP Int Inc ") and Intellipharmaceutics Corp (" IPC ") filed an assignment in bankruptcy on October 31, 2024 and KPMG Inc was appointed as the trustee-in-bankruptcy (the " Trustee ") of the Estates of the Bankrupt by the Official Receiver, subject to affirmation by the creditors of Trustee's
- IntelliPharmaCeutics International Inc. Profile - MarketWatch
IntelliPharmaCeutics International Inc company facts, information and financial ratios from MarketWatch
- Intellipharmaceutics International 2025 Company Profile: Stock . . .
IntelliPharmaCeutics International Inc is a pharmaceutical company The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs
|